14 NOV

Le Meridien Cambridge Boston

Le MERIDIEN

Proventa International's 6th Annual

DRUG DISCOVERY BIOLOGY

STRATEGY MEETING EAST COAST USA 2022

Understanding Complex Structure, Properties and Dynamics of Biological Phenomena in Drug Discovery: Emerging Tools and Next Generation Drug Target Characterization, Validation and Safety Profiling

Target ID & Validation | Drug Discovery | DMPK | ADME | AI/ML | Structural Biology | Biophysics | Screening Biology | PK/PD

Featuring Industry Leaders and Decision Makers

John Reilly
Chief Scientific Officer
Nereid Therapeutics

Li Peng
Chief Scientific Officer
Palleon Pharmaceuticals

Cara Williams
Vice President Head of Preclinical Biology: Inflammation & Immunology Research Unit
Pfizer

Brent Cezairliyan
Vice President, Biology
Octagon Therapeutics

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.

Karim Azer
VP, Head of Platform & Discovery
Axcella

Vibha Jawa
Executive Director, Nonclinical Disposition and Bioanalysis
Bristol-Myers Squibb

OUR SPONSORS

药明康德 WuXi AppTec

bit.bio

BasePair Biotechnologies, Inc.

BIOIVT

Cayman Chemical

Click here to find out what our clients think about our

STRATEGY MEETINGS!

Register Now! →

proventainternational.com

UK: +44 (0)20 3314 0100 | **US:** +1 (617) 614 0377

info@proventainternational.com

Proventa International

@proventaintl

@proventainternational

PROVENTA INTERNATIONAL

Proventa International's Strategy Meetings are a completely unique experience.

DRUG DISCOVERY BIOLOGY
STRATEGY MEETING
EAST COAST USA 2022

14 NOV

Our Vision



To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

There is an increasing need to sort, understand and utilize novel approaches to leverage the value of data generated by industry and academia towards generating new ideas and applications to its full potential. In doing so, we hope to replace costly techniques with the future alternatives and maximize predictive technologies in drug discovery programs spanning all stages of preclinical, clinical and beyond. At Proventa's 4th Annual Drug Discovery Biology Strategy Meeting in Boston, senior leaders in biology drug discovery will gather for candid and strategic discussions to ensure the most impactful challenges are being addressed and solutions uncovered.

Join Your Peers and Leave With Practical Benchmarking Opportunities in:

- Understanding recent advances and alternatives for drug discovery stages discovery, development and preclinical stages that could lead to cost cutting, efficiency and early detection
- Leveraging multi-omics analysis data, its advantages and limitations to further the possibilities for drug discovery applications
- Exploring computational modeling in the drug discovery process to optimize data, safety dosage and precision for future use and replications
- Understanding and interpreting vast amount of free data and how to utilize it in each track on drug discovery for further studies in computation and modeling
- Optimizing strategies and methods for druggable targets, target identification and validation to enhance compounds and transcend limits
- Pharmacological modalities that transcend the limits while retaining their key advantages on difficult to drug proteins
- Exploring the discrepancy in drug metabolism between different genders and ethnic diversification that could lead to understanding the pharmacokinetics distinction between genders and ethnicity
- This strategy meeting is a closed door round table discussion with 10-12 industry leaders that delves in current issues, practical ideas, timely concepts, hot topics, challenges and possible solutions
- Collaborative approaches and networking opportunities with different top-tier industry solution providers

SENIORITY OF ATTENDEES



- Director Level
- President / VP
- Department Head
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist
- Other

Facilitator Faculty

Henry Lu
VP & Head of Discovery Biology
Wuxi AppTec

Letian Kuai Ph.D
Executive Director of HitS-RSD & CSO of Crelux
Wuxi AppTec

Andreas Schoop
Head of Medicinal Chemistry
WuXi AppTec

Dominic Hussey
Territorial Head-EMEA Sales
Bit.Bio

Scott Heyward
Leading Product Development and Scientific Engagement
BioIVT Inc

Terri Almos
Executive Director, Emerging Science & Innovation Inflammation & Immunology
Pfizer

Karim Azer
VP, Head of Platform & Discovery
Axcella

Carla Bauer
Associate Director, Strategic Transactions, Business Development & Licensing
Novartis

Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity

Matthew Calabrese
Senior Director and Head of Structural and Molecular Sciences
Pfizer

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.

Brent Cezairliyan
Vice President, Biology
Octagon Therapeutics

Rob Foti
Senior Director, Preclinical Development (ADME & Discovery Toxicology)
MERCK

Vibha Jawa
Executive Director, Nonclinical Disposition and Bioanalysis
Bristol-Myers Squibb

Matthew Lech
Principal Research Scientist
Pfizer

Jing Li
Executive Director Biology
PTC Therapeutics, Inc.

Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Li Peng
Chief Scientific Officer
Palleon Pharmaceuticals

Nisha Perez
Senior Director, Head of DMPK
ROME Therapeutics

John Reilly
Chief Scientific Officer
Nereid Therapeutics

Cara Williams
Vice President Head of Preclinical Biology: Inflammation & Immunology Research Unit
Pfizer

Our Sponsors

Lead Sponsor

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.
http://www.wuxiapptec.com

VISIT WEBSITE

Co-host Sponsors

Bit.bio is an award-winning human synthetic biology enterprise based in Cambridge, UK. bit.bio's mission is to code cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease.

VISIT WEBSITE

Base Pair Biotechnologies is based just 10 miles south of the Houston, Texas Medical Center. Our team of 11 scientists has a combined 50+ person-years of experience in developing aptamers. Base Pair owns the sole worldwide rights to patents for *multiplexed* aptamer discovery. We have the capability to select aptamers to up to 30 protein, peptide, or small molecule targets in true competitive, multiplexed fashion. The resulting aptamers are therefore more specific for their particular targets. Using this technology, we have completed contracts from the National Cancer Institute, the CDC, and many large pharma and biotech firms.

VISIT WEBSITE

XenoTech, now a BioIVT company, is a specialized global CRO assisting pharmaceutical companies and researchers to investigate safety-related properties of novel therapeutics through nonclinical testing. We offer a comprehensive array of test systems and services to explore a drug candidate's metabolism and drug-drug interaction (DDI) potential. Our extensive collection of high quality test systems equips customers worldwide to perform their own studies, including an expansive inventory of plateable and suspension hepatocytes, complementary cell media, subcellular fractions, and more. In addition to providing critical services and test systems to our customers, we provide many learning resources for the drug development community by hosting seminars and webinars and frequently updating our website's repository with high-quality content such as posters, publications, and blog posts. By providing these products, services, and resources, XenoTech facilitates development of safer drugs, faster-- equipping clients with tools they need to make new treatments available to patients who need them.

VISIT WEBSITE

Cayman Chemical provides preclinical discovery and development services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of over 150 highly skilled scientists with expertise in medicinal and computational chemistry, structure-based drug design, complex multi-step organic synthesis, analytical chemistry, biomarker development, immunology, metabolism, cell biology, sample analysis, screening, and custom assay development. We offer a personalized, flexible approach that enables our clients to accelerate their drug discovery and development through a single-source partner, from novel drug design and synthesis to target identification and validation.

VISIT WEBSITE

Global Sponsorship Opportunities

Proventa's end-to-end consulting division gather real-time business intelligence on the industry's **needs, challenges, budgets** and **investment areas**. We combine this information with your specific needs to enhance your business development strategy. With the wealth of intel we provide, Proventa guarantees tangible results for your business within twelve months of the event.

For Sponsorship Opportunites please contact:
SPONSORSHIP TEAM: info@proventainternational.com | +44 (0) 2070961222

How it Works?

Real insights are shared in conversations, not lectures. That's why our unique **roundtable** format guarantees real learning and ensures you only attend discussions that deliver value to you.

Join as many as four roundtable discussions, each with up to 20 other subject experts, networking with top-level peers in an informal, relaxed and sociable environment.

Simply follow the steps below to select your roundtable discussions and we'll create your own personalised agenda for the day:

01 EXPLORE THE FULL AGENDA

Select which roundtable discussions you would like to join. Our sessions are divided among 6 themed tracks for easy selection - you can choose to join any session you like.

02 COMPLETE YOUR SCHEDULING FORM

Select your preferred roundtable discussion for each time slot. We will send this form out via email a few weeks before the event - be sure to get your first choice by completing the form quickly.

03 ENJOY YOUR PERSONALISED EXPERIENCE

Join your selected roundtable sessions on the day. We will give you your personalised agenda containing the time and room assignments of your chosen roundtable discussions so you won't miss it.

Agenda at a Glance

Drug Discovery Biology Strategy Overview 14th of November, 2022 – Cambridge, Boston - Le Meridien Hotel

TIME EST	TRACK 1 HIT IDENTIFICATION & VALIDATION	TRACK 2 STRUCTURAL BIOLOGY & BIOPHYSICS	TRACK 3 DMPK, ADME & TOXICOLOGY	TRACK 4 IN VIVO & IN VITRO PHARMACOLOGY	TRACK 5 IN SILICO & RNA BIOLOGICS	TRACK 6 STRATEGIC PARTNERSHIP & COLLABORATION
ROOM ►	Jerome C. Hunsaker C	Jerome C. Hunsaker C	Jerome C. Hunsaker C	Lan Jen Chu	Margaret L.A. Macvicar	Edward Pennell Brooks
08:00 - 08:30	REGISTRATION AND WELCOME					
08:30 - 09:00	OPENING KEYNOTE PRESENTATION ADME Challenges and Strategies for Protein Degraders					
09:00 - 10:00	Optimizing The Target Identification and Validation Processes: Select Novel and Human Disease Translatable Targets Through Genetics, Cellular, Molecular, Omics, and Other Approaches	Biomolecular Condensates: Structural and Biophysical Approaches for Drug Discovery	PB/PK Toxicity Modeling: Lowering The Risk Of Drug Discovery Failure Due To Low Efficacy Rate And High Toxicity Rate	Strengths and Limitations of Animal Models in Drug Development	Big Data and AI: Integration and Harnessing the Full Potential of Massive Data Sets to use in Small Molecule Drug Discovery	Collaborative Approach of Industry and Academia for Accelerated Development and New Breakthroughs
10:00 - 10:10	REFRESHMENT BREAK					
10:10 - 10:30	NETWORKING / 1-1 MEETINGS					
10:30 - 10:50	NETWORKING / 1-1 MEETINGS					
10:50 - 11:10	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10 SOLUTION	Leveraging the Power of Multi-Omics in Drug Discovery: Maximizing the Potential in Target Identification and Safety Profiling WUXI APPTEC	The Future of Protein Structure Prediction: Advantages, Applications and Limitations in Drug Discovery WUXI APPTEC	Utilizing Specialized Non-Clinical Resources to Support Drug Development BIOIVT	Addressing the current challenges of in vitro cell models and their translation into the clinic BIT.BIO	In vitro bioassays and in vivo pharmacology to support RNA biology WUXI APPTEC	
12:10 - 13:10	NETWORKING LUNCH					
13:10 - 13:40	AFTERNOON KEYNOTE PRESENTATION The New Frontiers of DNA Encoded Library Technology					
13:40 - 14:40	Identifying Potential Drug Targets through Integrating Structural Characterization, Biological Data and Literature	Structural Biology and Biophysics for the next generation of First-in-Class targets	Maximizing And Improving DMPK Accuracy For Efficiency And Cost Effectivity	Engineering The Next Generation Of Organoids And 3D Cell Models For Testing And Predicting In Pharmacology	A Computational and Systems Biology Based Approach to Investigating Disease Biology in Drug Discovery for Efficacy, Safety, Translation to the Clinic and Efficiency of Trials and Improved Likelihood of Success	Funding Vehicles for Partnerships and Collaborations
14:40 - 14:50	REFRESHMENT BREAK					
14:50 - 15:10	NETWORKING / 1-1 MEETINGS					
15:10 - 15:30	NETWORKING / 1-1 MEETINGS					
15:30 - 15:50	NETWORKING / 1-1 MEETINGS					
15:50 - 16:50	Expanding The Druggable Genome: How Can We Access Greater Target Space To Better Treat Disease	Emerging Strategies for Targeted Protein Degradation through Small Molecule: Pharmacological Modality that Induce Protein Degradation to Transcend the Limits while Retaining their Key Advantages on Difficult to Drug Proteins	Predicting Toxicity In Drug Development Through AI/ML A Cheaper And Time Efficient Approach Compared To Animal Testing	A More Extensive Approach to Pre-clinical Study for Drug Development: Utilization of Novel Strategies for In Vivo & In Vitro Methods		Strategic Guide To Maximizing Value Through Partnerships: 3 Pillars For Long-Term Success In Drug Discovery And Development
16:50 - 17:50	DRINKS & CANAPES RECEPTION					

Event Day

OPENING KEYNOTE PRESENTATION

8:30 – 9:00 EST

ADME Challenges and Strategies for Protein Degraders

- Degraders as a subset of Beyond rule-of-five (bRo5) compounds
- In Vitro–In Vivo Correlation (IVIVC) and In Vitro–In Vivo Extrapolation (IVIVE)
- In-Vivo PK and PK/PD studies -mitigation of potential roadblocks

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.

AFTERNOON KEYNOTE PRESENTATION

13:10 - 13:40 EST

The New Frontiers of DNA Encoded Library Technology

WUXI APPTEC

Letian Kuai Ph.D
Executive Director of HitS-RSD & CSO of Crelux
WuXi AppTec

TRACK 1:
HIT IDENTIFICATION & VALIDATION

Improve efficiency in finding novel therapeutic targets continues to be an immediate priority & hurdle in the pharma and biotech industry. This track aims to explore the undruggable space: Utilizing AI/ML,optimizing target identification pathway and more. Where is the next druggable target frontier to stay viable?

09:00 – 10:00 EST

ROUNDTABLE 1:
Optimizing The Target Identification and Validation Processes: Select Novel and Human Disease Translatable Targets Through Genetics, Cellular, Molecular, Omics, and Other Approaches

- Employing methods in selecting the optimal pathways/targets, and in generating novel insights for human disease relevance, with the focus on translatability
- Recent success stories: Omics and other approaches such as phenotypic screens, to identify and prioritize pathways/targets for drug intervention
- Discussions on small molecule druggability: An ever expanding space with protein degraders, splicing modulators and other strategies

Jing Li
Executive Director Biology
PTC Therapeutics, Inc.

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
Choosing the right tool(s) for early hit discovery

- What is your trusted tool in hit discovery?
- How to increase the success rate in hit discovery?
- In an Alphafold and machine learning era, can the order of drug discovery funnels be changed?

WUXI APPTEC

Letian Kuai Ph.D
Executive Director of HitS-RSD & CSO of Crelux
WuXi AppTec

13:40 – 14:40 EST

ROUNDTABLE 3:
Identifying Potential Drug Targets Through Integrating Structural Characterization, Biological Data And Literature

- What strategies are currently being employed?
- Does the strategy differ by therapeutic area?
- Can machine learning aid in the integration?
- Is there value in open source sharing of target assessments?

Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

15:50 – 16:50 EST

ROUNDTABLE 4:
Expanding The Druggable Genome: How Can We Access Greater Target Space To Better Treat Disease

- Advances in therapeutic targeting of RNA
- Developing therapeutics targeting disordered proteins
- Evaluating target specificity of novel therapeutic modalities

Brent Cezairliyan
Vice President, Biology
Octagon Therapeutics

Event Day

TRACK 2:
STRUCTURAL BIOLOGY & BIOPHYSICS

A key idea in biology is that structure, to a large extent, dictates function. The rapid development of sensitive biophysical methods and emerging technologies that interrogate compound properties and mechanisms of action is transforming drug discovery.

09:00 – 10:00 EST

ROUNDTABLE 1:
Biomolecular Condensates: Structural and Biophysical Approaches for Drug Discovery

- Successes, experiences, and challenges in drugging IDPs/IDRs: reasons, possibilities, new approaches
- Characterization of IDPs and IDRs through biophysical approaches
- Predicting IDR structure that could lead to future advancement
- Novel approaches and recent advancement in targeting of IDPs and IDRs; small molecules and novel modalities

John Reilly
Chief Scientific Officer
Nereid Therapeutics

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
The Future of Protein Structure Prediction: Advantages, Applications and Limitations in Drug Discovery

- What are the most promising applications for predicting protein structures
- Validation of protein structure predictions and the role of X-ray Crystallography
- How far are we away to predict protein structures including ligand binding

Andreas Schoop
Head of Medicinal Chemistry
WuXi AppTec

WUXI APPTEC

13:40 – 14:40 EST

ROUNDTABLE 3:
Structural Biology and Biophysics for the next generation of First-in-Class targets

- What information and insights from Structural Biology will be most critical to the field of drug discovery over the next 5 years
- Approaches to study multi-subunit and physiologically relevant assemblies
- Applying medium resolution biophysical tools to inform mechanism of action
- Building efficient tools through protein engineering

Matthew Calabrese
Senior Director and head of Structural and Molecular Sciences
Pfizer

15:50 – 16:50 EST

ROUNDTABLE 4:
Emerging Strategies for Targeted Protein Degradation through Small Molecule: Pharmacological Modality that Induce Protein Degradation to Transcend the Limits while Retaining their Key Advantages on Difficult to Drug Proteins

- Finding new degrader modalities for enabling targeted degradation and discovery of new small molecule degraders targeting the difficult to drug protein and the undruggable
- Exploring the possibilities of targeted protein degradation to the undruggable space through small molecule
- PROTAC advantages compared with traditional small molecule

Rob Foti
Senior Director, Preclinical Development (ADME & Discovery Toxicology)
MERCK

Event Day

TRACK 3:
DMPK, ADME & TOXICOLOGY

A primary source of drug candidate trial failure is attributed to inadequate efficacy and safety profiles. This track serves to highlight key topics and pressing challenges within the areas of drug metabolism, biotransformation, and drug toxicity.

09:00 – 10:00 EST

ROUNDTABLE 1:
PB/PK Toxicity Modeling: Lowering The Risk Of Drug Discovery Failure Due To Low Efficacy Rate And High Toxicity Rate

- Preclinical advancements in reducing the drug discovery failure rate
- PB/PK Toxicity Modeling
  - Advantages
  - Disadvantages
  - Limitations
  - Cost effectivity
  - Time efficiency
- What's next and how to combine with other technologies for drug safety

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
Utilizing Specialized Non-Clinical Resources to Support Drug Development

- Performing in vitro ADME studies with a trusted expert adds value, reduces risk, bolsters pipelines, and strengthens approval odds
- Most new drugs fail because of ADME/Tox
- Non-Clinical ADME testing is proven to reduce failures
- XenoTech has demonstrated VALUE with proven expertise and experience

Scott Heyward
Leading Product Development and Scientific Engagement
BioIVT Inc

BIOIVT

13:40 – 14:40 EST

ROUNDTABLE 3:
Maximizing And Improving DMPK Accuracy For Efficiency And Cost Effectivity

- Selecting the appropriate testing funnel and when to pivot to a different assay type for your scaffold
- RRR: adding PK modeling for rodent/higher species informed dose selection
- ADME modeling, how good are the in silico prediction tools out there?

Nisha Perez
Senior Director, Head of DMPK
ROME Therapeutics.

15:50 – 16:50 EST

ROUNDTABLE 4:
Predicting Toxicity In Drug Development Through AI/ML - A Cheaper And Time Efficient Approach Compared To Animal Testing

- In this session we will discuss the use of in silico tools and mining of preclinical and clinical datasets to improve the algorithms and reduce preclinical testing. We will also evaluate the value of utilizing AI/ML approach in reducing toxicity risk in animal testing and giving appropriate weight to toxicity prediction.

Vibha Jawa
Executive Director, Nonclinical Disposition and Bioanalysis
Bristol-Myers Squibb

TRACK 4:
IN VIVO & IN VITRO PHARMACOLOGY

This track will focus on challenges and solutions, innovative approaches, and technologies associated with modeling human disease through in vitro and in vivo assays to progress your early pharmacological research.

09:00 – 10:00 EST

ROUNDTABLE 1:
Strengths and Limitations of Animal Models in Drug Development

- Comparing animal models vs human cells/tissues in terms of :
  - Confidence in rationale for target selection
  - Dose projection
  - Cost effectiveness and time efficiency
  - Human translation
- Evaluation of other ex vivo substitutes in validation to cover for new modalities and efficiency of drug trials
- Gauging the industry preparedness in using other alternative tools to improve efficiency and advancements

Cara Williams
Vice President Head of Preclinical Biology: Inflammation & Immunology Research Unit, Pfizer

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
Addressing the current challenges of in vitro cell models and their translation into the clinic

The roundtable discussion will focus on the main challenges associated with in vitro human cell models as a platform for disease modelling and drug discovery, addressing issues such as:

- Benefits and problems of using human iPSC-derived cells
- The importance of consistent, scalable manufacturing process for iPSC-derived cells
- How next generation approaches such as precision cellular reprogramming, can accelerate in vitro drug discovery and translation into the clinic

Dominic Hussey
Territorial Head-EMEA Sales
Bit.Bio

BIT.BIO

Event Day

13:40 – 14:40 EST

ROUNDTABLE 3:
Engineering The Next Generation Of Organoids And 3D Cell Models For Testing And Predicting In Pharmacology

- Tackling the promises of organoids/technological advancements such as faster and better outcomes, due to lesser risks associated with research and development trials
- Evaluating the current significance and future of organoids and 3D cell models in the potential harnessing of cost-efficient personalized medicines
- Advantages and disadvantages in using organoids vs 3D cell models for toxicology pharmacology and comparison in culture condition, structure, maintenance and genomic stability
- Advantages of organoids as Living Biobanks for research purposes

Matthew Lech
Principal Research Scientist
Pfizer

15:50 – 16:50 EST

ROUNDTABLE 4:
A More Extensive Approach to Pre-clinical Study for Drug Development: Utilization of Novel Strategies for In Vivo & In Vitro Methods

- Predictive toxicity and Drug safety predictions for pre clinical study
  - Pros and Cons
  - Advantages and Disadvantages
  - Strengths and Limitations
- New developments in In Vivo/In Vitro pharmacology methods

Jing Li
Executive Director Biology
PTC Therapeutics, Inc.

TRACK 5:
IN SILICO & RNA BIOLOGICS

The utility of computational methods is widely used in various stages of drug discovery and development. From aiding target ID & validation, limiting the use of animal models in pharmacology to aiding rational drug design, this track will explore novel approaches and applications of in silico techniques to maximize productivity towards clinical success.

09:00 – 10:00 EST

ROUNDTABLE 1:
Big Data and AI: Integration and Harnessing the Full Potential of Massive Data Sets to use in Small Molecule Drug Discovery

- Challenges to incorporating data from data collection of biological (Drug target data, Exoms, Gene expressions, Cellular data and Omics), chemical, pharmacological (ADMET , In Vivo and In Vitro Assay) and clinical domains
- How and where can the massive data be used in drug discovery and development?
- What AI technologies are most appropriate for drug discovery
- Exploring data combination for different fields such as:
  - Omics for target discovery and compound optimization
  - Virtual Screening of ultra-Large libraries
  - DMPK / ADMET
  - In Vitro and In Vivo Pharmacology

Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
In Vitro Bioassays and In Vivo Pharmacology to Support RNA Biology

- What are typical cell based assay systems used in RNA Biology research?
- In vitro assays for off-target profiling and for cytotoxicity and immunotoxicity analyses
- For in vivo evaluation of RNA-targeting new modalities for Hepatitis B, neurodegenerative diseases, metabolic diseases, what are the clinically relevant models?

Henry Lu
VP & Head of Discovery Biology
Wuxi AppTec

WUXI APPTEC

13:40 – 14:40 EST

ROUNDTABLE 3:
A Computational and Systems Biology Based Approach to Investigating Disease Biology in Drug Discovery for Efficacy, Safety, Translation to the Clinic and Efficiency of Trials and Improved Likelihood of Success

- How data sciences, computational modeling and systems biology for investigating disease biology is useful in new drug discovery and development?
  - Pros and Cons
  - Advantages and Disadvantages
  - Strengths and limitations
- How can data sciences, computational modeling and systems biology help with safety, efficacy and efficiency of drug discovery
  - Time Wise
  - Budget Wise
  - Efficiency
- Sharing your experiences with data sciences, computational modeling and systems biology for drug discovery and development
- How to start if I want to apply data sciences, computational modeling and systems biology to investigate biological processes for our future drug discovery endeavour

Karim Azer
VP, Head of Platform & Discovery
Axcella

Event Day

TRACK 6:
STRATEGIC PARTNERSHIP & COLLABORATION

The pharma and biotech sector continues to seek ways to address challenges in R&D productivity, spending cuts, and volatile market conditions. Strategic partnerships and alliances have grown in importance to reduce cost, share risks and rewards while maximizing learning opportunities resulting from successful collaborations.

09:00 – 10:00 EST

ROUNDTABLE 1:
Collaborative Approach of Industry and Academia for Accelerated Development and New Breakthroughs

- Addressing the advantages and disadvantages of Collaboration
- Bridging the industry gap to foster effective collaborations
- Leveraging data efficiency and knowledge sharing for more effective, faster and diverse research
- Where and how to start the Decentralization of research and trials
- Addressing the possibilities of research and trial collaborations for future costs and efficacy

Li Peng
Chief Scientific Officer
Palleon Pharmaceuticals

11:10 – 12:10 EST

SOLUTION FOCUS ROUNDTABLE 2:
Drug Development Acceleration through Collaboration and Decentralization of Research and Trials that could Lead to Cost Cutting, Safety and Efficacy

13:40 – 14:40 EST

ROUNDTABLE 3:
Funding Vehicles for Partnerships and Collaborations

- Funding academic research – emerging science to co-discovery models
- The importance of venture capital funding in early innovation
- Build-to-buy startups

Terri Almos
Executive Director, Emerging Science & Innovation
Inflammation & Immunology
Pfizer

15:50 – 16:50 EST

ROUNDTABLE 4:
Strategic Guide To Maximizing Value Through Partnerships: 3 Pillars For Long-Term Success In Drug Discovery And Development

- Begin with the end in mind: Choosing a partner to build the most value for your company
- Create a strong foundation: Best practices for negotiation and contracting, clarity is key
- Get to work: Execution is essential to unlocking potential value, we will discuss resources and processes you need to stay on track

Carla Bauer
Associate Director, Strategic Transactions,
Business Development & Licensing
Novartis

DRINKS & CANAPES RECEPTION

Please contact:
info@proventainternational.com
to register your interest

OR
SCAN HERE
TO REGISTER

Le MERIDIEN

DRUG DISCOVERY BIOLOGY
STRATEGY MEETING
EAST COAST USA 2022

14 NOV



Venue

Le Meridien Hotel - Cambridge, Boston

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort.

BOOK ONLINE RESERVATION →
For more details email: s

MAP & DIRECTIONS →

OUR FACE-TO-FACE MEETING IN OCTOBER & NOVEMBER 2022

Strategy Meeting Zurich and Boston

Zurich - Europe

OCT 10 MON — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 10 MON — CLINICALTRIALSUPPLYCHAIN
Clinical Trial Supply Chain Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 11 TUE — BIOMANUFACTURING
Biomanufacturing Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 11 TUE — CELLANDGENETHERAPY
Cell & Gene Therapy Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 12 WED — REGULATORYAFFAIRS
Regulatory Affairs Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 12 WED — CHEMISTRYMANUFACTURINGCONTROL
CMC Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

OCT 13 THUR — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Radisson Blu Hotel Zurich Airport

Boston/Cambridge MA - US East Coast

NOV 08 TUE — ONCOLOGY
Oncology Strategy Meeting 2022
Le Meridien Cambridge

NOV 09 WED — CLINICALOPERATIONS
Clinical Operations Strategy Meeting 2022
Le Meridien Cambridge

NOV 10 THUR — REGULATORYAFFAIRS
Regulatory Affairs Strategy Meeting 2022
Le Meridien Cambridge

NOV 14 MON — DRUG DISCOVERY BIOLOGY
Drug Discovery Biology Strategy Meeting 2022
Le Meridien Cambridge

NOV 15 TUE — MEDICINALCHEMISTRY
Medicinal Chemistry Strategy Meeting 2022
Le Meridien Cambridge

Understanding Complex Structure, Properties and Dynamics of Biological Phenomena in Drug Discovery: Emerging Tools and Next Generation Drug Target Characterization, Validation and Safety Profiling

Register Now! →
info@proventainternational.com